-transparent.png){kind=logo}
The pharmacokinetics of a novel praziquantel preparation (Distocide) were investigated in Sudanese patients with hepatosplenic schistosomiasis and in healthy volunteers, and compared with those of Biltricide. The results of the first study indicated greater (P less than 0.05) plasma concentrations of Biltricide at 1.5, 2, 3 and 5 h after administration than with Distocide; plasma elimination half-lives (t 1/2) were not significantly different. In patients with hepatosplenic schistosomiasis, higher plasma levels of Distocide were noted (P less than 0.05 at 8 h) compared to healthy controls; however, due to wide inter-individual variations, there were no significant differences in maximum plasma concentration, time to maximum plasma concentration, area under the plasma concentration curve (AUC), volume of distribution, or clearance; t 1/2 was greater (P less than 0.05) in patients (11.9 +/- 5.4 h) than controls (2.3 +/- 0.4 h). In the presence of food, higher plasma concentrations of Distocide occurred compared to the fasting state; AUCs were greater (P less than 0.01) in both food groups, although the values of t 1/2 were shorter. The lower plasma levels and longer duration of action of Distocide may be advantageous in reducing side effects and prolonging exposure of the schistosomes to the drug.
M E Mandour, and
H el Turabi, and
M M Homeida, and
T el Sadig, and
H M Ali, and
J L Bennett, and
W J Leahey, and
D W Harron
November 1998,
Biopharmaceutics & drug disposition,
M E Mandour, and
H el Turabi, and
M M Homeida, and
T el Sadig, and
H M Ali, and
J L Bennett, and
W J Leahey, and
D W Harron
January 1995,
Diagnostic microbiology and infectious disease,
M E Mandour, and
H el Turabi, and
M M Homeida, and
T el Sadig, and
H M Ali, and
J L Bennett, and
W J Leahey, and
D W Harron
July 2017,
Zhongguo xue xi chong bing fang zhi za zhi = Chinese journal of schistosomiasis control,
M E Mandour, and
H el Turabi, and
M M Homeida, and
T el Sadig, and
H M Ali, and
J L Bennett, and
W J Leahey, and
D W Harron
February 2021,
Clinical pharmacokinetics,
M E Mandour, and
H el Turabi, and
M M Homeida, and
T el Sadig, and
H M Ali, and
J L Bennett, and
W J Leahey, and
D W Harron
December 1987,
British journal of clinical pharmacology,
M E Mandour, and
H el Turabi, and
M M Homeida, and
T el Sadig, and
H M Ali, and
J L Bennett, and
W J Leahey, and
D W Harron
January 1991,
Biomedica biochimica acta,
M E Mandour, and
H el Turabi, and
M M Homeida, and
T el Sadig, and
H M Ali, and
J L Bennett, and
W J Leahey, and
D W Harron
October 2014,
The Journal of pharmacy and pharmacology,
M E Mandour, and
H el Turabi, and
M M Homeida, and
T el Sadig, and
H M Ali, and
J L Bennett, and
W J Leahey, and
D W Harron
January 1989,
The Japanese journal of antibiotics,
M E Mandour, and
H el Turabi, and
M M Homeida, and
T el Sadig, and
H M Ali, and
J L Bennett, and
W J Leahey, and
D W Harron
February 1997,
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
M E Mandour, and
H el Turabi, and
M M Homeida, and
T el Sadig, and
H M Ali, and
J L Bennett, and
W J Leahey, and
D W Harron
December 2007,
Journal of clinical pharmacy and therapeutics,
